Ensysce Biosciences Net Income Over Time
| ENSC Stock | USD 0.43 0.01 2.14% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Ensysce Biosciences Performance and Ensysce Biosciences Correlation. Will Biotechnology sector continue expanding? Could Ensysce diversify its offerings? Factors like these will boost the valuation of Ensysce Biosciences. Projected growth potential of Ensysce fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Ensysce Biosciences data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (6.35) | Revenue Per Share | Quarterly Revenue Growth (0.86) | Return On Assets | Return On Equity |
Investors evaluate Ensysce Biosciences using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Ensysce Biosciences' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Ensysce Biosciences' market price to deviate significantly from intrinsic value.
It's important to distinguish between Ensysce Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Ensysce Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Ensysce Biosciences' market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income Analysis
Compare Ensysce Biosciences and related stocks such as Soligenix, Titan Pharmaceuticals, and Oragenics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SNGX | (1.2 M) | (2.4 M) | (4.2 M) | (10.1 M) | (6.7 M) | (7.8 M) | (3.2 M) | (7.1 M) | (8.9 M) | (9.4 M) | (17.7 M) | (12.6 M) | (13.8 M) | (6.1 M) | (8.3 M) | (7.4 M) | (7.8 M) |
| OGEN | (1.7 M) | (7.7 M) | (13.1 M) | (16.1 M) | (5.8 M) | (11.7 M) | (7 M) | (6.7 M) | (9.9 M) | (15.6 M) | (26.4 M) | (15.7 M) | (14.3 M) | (20.7 M) | (10.6 M) | (9.5 M) | (10 M) |
| KALA | (10.7 M) | (10.7 M) | (10.7 M) | (10.7 M) | (19.4 M) | (16.7 M) | (33.2 M) | (42.2 M) | (66.7 M) | (94.3 M) | (104.3 M) | (142.6 M) | (44.8 M) | (42.2 M) | (38.5 M) | (34.7 M) | (36.4 M) |
| XBIO | (6.3 M) | (6.3 M) | (6.3 M) | (8.6 M) | (14.3 M) | (12.5 M) | (54.2 M) | (3.6 M) | (7.3 M) | (12.8 M) | (10.9 M) | (5.6 M) | (6.6 M) | (4.1 M) | (4 M) | (4.6 M) | (4.8 M) |
| AIM | (1.8 M) | (9 M) | (17.4 M) | (16.2 M) | (17.4 M) | (15.2 M) | (7.5 M) | (8.3 M) | (9.8 M) | (9.4 M) | (14.4 M) | (19.1 M) | (19.4 M) | (29 M) | (17.3 M) | (15.6 M) | (16.4 M) |
| VYNE | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (14.1 M) | (29.1 M) | (51.4 M) | (70.5 M) | (255.6 M) | (73.3 M) | (23.2 M) | (28.5 M) | (39.8 M) | (35.9 M) | (37.6 M) |
| KZIA | (17.1 M) | 1.3 M | (1 M) | (7.5 M) | (7.1 M) | (12.1 M) | (10.7 M) | (6 M) | (10.3 M) | (12.5 M) | (8.4 M) | (25 M) | (20.5 M) | (26.8 M) | (20.7 M) | (23.8 M) | (25 M) |
| CANF | (3.7 M) | (6.7 M) | (5.6 M) | (8.3 M) | (6.1 M) | (4.8 M) | (6.9 M) | (5 M) | (6.6 M) | (12.6 M) | (14.4 M) | (12.6 M) | (10.2 M) | (7.6 M) | (7.9 M) | (7.1 M) | (7.4 M) |
Ensysce Biosciences and related stocks such as Soligenix, Titan Pharmaceuticals, and Oragenics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Ensysce Biosciences financial statement analysis. It represents the amount of money remaining after all of Ensysce Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Ensysce Biosciences | ENSC |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 7946 Ivanhoe Avenue, |
| Exchange | NASDAQ Exchange |
USD 0.4306
Check out Ensysce Biosciences Performance and Ensysce Biosciences Correlation. For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Ensysce Biosciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.